Tenaya Therapeutics, Inc.
NASDAQ: TNYA. Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
US
- Alpha ID
- alpha:company:810631da-42e1-450b-a8db-7d602d72ce6d
- SEC CIK
- 0001858848
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 20, 2026
- Newest evidence
- Apr 16, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Not published
- Chair
- Not published
- Independent
- 7 / 88 directors published
- Published claims
- 252 distinct sources
- Evidence records
- 30 pinned
- Source conflicts
- 0None open
Built from 2 distinct sources and 3 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
DIRECTOR APPOINTED
Amy Burroughs, M.B.A. seat on Tenaya Therapeutics, Inc., effective 2022-01-01.
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Board of directors
Evidence8 directors published. 7 of 8 with a published determination are independent.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Amy Burroughs, M.B.A. | Independent | 2022 | AuditCompensation | Source reportedE2 |
| Catherine Stehman-Breen, M.D. | Independent | 2020 | None published | Source reportedE2 |
| Deepak Srivastava, M.D. | Independent | 2016 | Nominating/Governance, chair | Source reportedE2 |
| Faraz Ali, M.B.A. | Not independent | 2018 | None published | Source reportedE2 |
| Jeffrey T. Walsh, M.B.A. | Independent | 2020 | Audit, chairCompensation | Source reportedE2 |
| June Lee, M.D. | Independent | 2021 | Compensation, chair | Source reportedE2 |
| Karah Parschauer, J.D. | Independent | 2021 | Audit | Source reportedE2 |
| R. Sanders Williams, M.D. | Independent | 2016 | Nominating/Governance | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | Jeffrey T. Walsh, M.B.A. | Jeffrey T. Walsh, M.B.A., Amy Burroughs, M.B.A., Karah Parschauer, J.D. | Not described in the published record |
| Compensation | June Lee, M.D. | June Lee, M.D., Amy Burroughs, M.B.A., Jeffrey T. Walsh, M.B.A. | Not described in the published record |
| Nominating/Governance | Deepak Srivastava, M.D. | Deepak Srivastava, M.D., R. Sanders Williams, M.D. | Not described in the published record |
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Financials and market context
EvidenceGovernance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- LeadershipNot reviewed. Executive leadership carries operating authority.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Amy Burroughs, M.B.A.Directorcompany:810631da-42e1-450b-a8db-7d602d72ce6d:leadership_role:7
- Catherine Stehman-Breen, M.D.Directorcompany:810631da-42e1-450b-a8db-7d602d72ce6d:leadership_role:8
- Deepak Srivastava, M.D.Directorcompany:810631da-42e1-450b-a8db-7d602d72ce6d:leadership_role:9
- Faraz Ali, M.B.A.Directorcompany:810631da-42e1-450b-a8db-7d602d72ce6d:leadership_role:10
- Jeffrey T. Walsh, M.B.A.Directorcompany:810631da-42e1-450b-a8db-7d602d72ce6d:leadership_role:11
- June Lee, M.D.Directorcompany:810631da-42e1-450b-a8db-7d602d72ce6d:leadership_role:12
- Karah Parschauer, J.D.Directorcompany:810631da-42e1-450b-a8db-7d602d72ce6d:leadership_role:13
- R. Sanders Williams, M.D.Directorcompany:810631da-42e1-450b-a8db-7d602d72ce6d:leadership_role:14
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 3 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 20, 2026. Cited by 6 Claims.
- E2sec proxy. Published Apr 16, 2026. Retrieved Apr 25, 2026. Cited by 8 Claims.
- E3governance_people_committees. sec proxy. Cited by 11 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 20, 2026- Amy Burroughs, M.B.A. seat on Tenaya Therapeutics, Inc., effective 2022-01-01.
- June Lee, M.D. seat on Tenaya Therapeutics, Inc., effective 2021-01-01.
- Karah Parschauer, J.D. seat on Tenaya Therapeutics, Inc., effective 2021-01-01.
- Catherine Stehman-Breen, M.D. seat on Tenaya Therapeutics, Inc., effective 2020-01-01.
- Jeffrey T. Walsh, M.B.A. seat on Tenaya Therapeutics, Inc., effective 2020-01-01.
- Faraz Ali, M.B.A. seat on Tenaya Therapeutics, Inc., effective 2018-01-01.
- Deepak Srivastava, M.D. seat on Tenaya Therapeutics, Inc., effective 2016-01-01.
- R. Sanders Williams, M.D. seat on Tenaya Therapeutics, Inc., effective 2016-01-01.



